Skip to content
Research Article Open access CC BY 4.0

Adverse Events Following COVID-19 Vaccination in Anambra State, South East Nigeria

Obi-Nwosu Amaka L., Eze Chijioke Eze, Ibeh Christian C., Nwosu Betrand O., Ezemenahi Sylvia I., Azudialu Bede C., Ulochukwu Chinyere M., Obi-Nwosu Ifechukwu D.

Asian Journal of Medicine and Health · pp. 59–68 · Published 22 Jul 2023

10.9734/ajmah/2023/v21i10878

Abstract

The use of safe and effective vaccination is critical to control of pandemics. Vaccines remain the bedrock in management of infectious diseases outbreaks. There has always been hesitancy to vaccination due to the fear of adverse events. It is therefore necessary that post vaccination adverse events be studied for effective enlightenment of the general populace. Objective: We aimed to investigate the adverse reactions following COVID-19 vaccination in Anambra state, South East Nigeria. Methods: Using a cross-sectional study design, 433 subjects aged 18years or older who had received any dose of the four COVID-19 vaccines (Moderna, Astra Zeneca, Pfizer and J&J (Janssen) were selected using a multi-stage sampling technique. The subjects were interviewed about COVID-19 vaccine related adverse reactions using self-administered questionnaire. Descriptive statistics (mean, standard deviation) and analytical statistics were performed and level of significance set at < 0.5 using SPSS V24. Results: Of the 433 subjects finally studied, 62.8% were females and 22.4% were married. About 69% of them had tertiary education.  Those who received the second dose of their respective vaccines were 44.8% while 11.5% had received a booster dose. Approximately half (50.3%) of the COVID-19 vaccines had adverse events. The most common types of adverse events (AEs) were local pain at injection site (62.1%) followed by headache (54.3%) and then fatigue (50.1%). Majority of the adverse events were mild to moderate in severity.  Those who had only local adverse events were 70.2% while 45% had systemic adverse events. Conclusion: In this study, severe adverse events were rare, even after the second dose. Most of the adverse events were mild to moderate in severity and therefore awareness campaign should be created to enlighten the community about the adverse effects of COVID-19 vaccines.

COVID - 19 vaccination adverse events local systemic severity

References (35)

  1. 1 Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal [DOI]
  2. 2 Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK [DOI]
  3. 3 Herd Immunity: Understanding COVID-19 [DOI]
  4. 4 Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study [DOI]
  5. 5 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine [DOI]
  6. 6 Acceptance and attitudes toward COVID-19 vaccines: A cross-sectional study from Jordan [DOI]
  7. 7 Individual and social determinants of COVID-19 vaccine uptake [DOI]
  8. 8 The public’s role in COVID-19 vaccination: Human-centered recommendations to enhance pandemic vaccine awareness, access, and acceptance in the United States [DOI]
  9. 9 Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study [DOI]
  10. 10 Enhancing COVID-19 Vaccines Acceptance: Results from a Survey on Vaccine Hesitancy in Northern Italy [DOI]
  11. 11 COVID-19: Mechanisms of Vaccination and Immunity [DOI]
  12. 12 Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria [DOI]
  13. 13 COVID-19 vaccination in Nigeria: A rapid review of vaccine acceptance rate and the associated factors [DOI]
  14. 14 Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System [DOI]
  15. 15 COVID-19 vaccine hesitancy among staff and students in a Nigerian tertiary educational institution [DOI]
  16. 16 Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience [DOI]
  17. 17 COVID-19 vaccine hesitancy and willingness to pay: Emergent factors from a cross-sectional study in Nigeria [DOI]
  18. 18 Adverse effects following COVID-19 vaccination in Iran [DOI]
  19. 19 Adverse Effects of the COVID-19 Vaccine Reported by Lecturers and Staff of Kabul University of Medical Sciences, Kabul, Afghanistan [DOI]
  20. 20 “They have produced a vaccine, but we doubt if COVID-19 exists” : correlates of COVID-19 vaccine acceptability among adults in Kano, Nigeria [DOI]
  21. 21 Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021 [DOI]
  22. 22 Non-life-threatening adverse reactions from COVID-19 vaccine; a cross-sectional study with self-reported symptoms among Ghanaian healthcare workers [DOI]
  23. 23 Why many African countries may not achieve the 2022 COVID-19 vaccination coverage target [DOI]
  24. 24 Public Health Surveillance for Adverse Events Following COVID-19 Vaccination in Africa [DOI]
  25. 25 Determinants of COVID-19 vaccine uptake among Nigerians: evidence from a cross-sectional national survey [DOI]
  26. 26 Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study [DOI]
  27. 27 Adverse Events Following COVID-19 Vaccination in Rivers State, Nigeria [DOI]
  28. 28 Analysis of COVID-19 vaccine adverse event using language model and unsupervised machine learning [DOI]
  29. 29 Adverse events following COVID-19 vaccination in Kwara State, North-central Nigeria [DOI]
  30. 30 Cohort Event Monitoring for Safety Signal Detection in Adult Individuals 18 Years and Above after Immunisation with Coronavirus Disease 2019 Vaccines in Nigeria [DOI]
  31. 31 Side Effect Profile of COVID-19 Vaccine among Health Workers in a Tertiary Health Institution in South-South Nigeria [DOI]
  32. 32 Prevalence and Predictors of Adverse Reactions to COVID-19 AstraZeneca Vaccine among Healthcare Staff of General Hospital Ilorin, North-Central, Nigeria [DOI]
  33. 33 COVID-19 vaccination hesitancy, misinformation and conspiracy theories on social media: A content analysis of Twitter data [DOI]
  34. 34 Sample Size Determination [DOI]
  35. 35 E-31 CT, SPECTの統合画像処理による三次元画像表示システムを用いた難治性てんかんに対する外科治療の試み

Cited by 1

Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial

A. Salako, A. Musa, F. Ige · Scientific Reports · 2025

Related research

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

1

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.